Hangzhou, China

Chen Pan

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Hangzhou Tianlong Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chen Pan. Retrieved from https://idiyas.com/inventor/chen-pan-d1m4go2g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Chen Pan

Introduction

Chen Pan is a notable inventor based in Hangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in vaccine development. His work is recognized for its potential impact on public health.

Latest Patents

Chen Pan holds a patent for a "Respiratory Syncytial Virus mRNA Vaccine, and Preparation Method Therefor and Use Thereof." This innovative vaccine aims to address a critical health issue, showcasing his commitment to advancing medical science. He has 1 patent to his name.

Career Highlights

Chen Pan is currently employed at Hangzhou Tianlong Pharmaceutical Co., Ltd. His role at this esteemed company allows him to work on cutting-edge research and development projects. His expertise in vaccine technology is invaluable to the organization.

Collaborations

Chen Pan collaborates with talented colleagues, including Gengshen Song and Kai Dong. Together, they contribute to the advancement of pharmaceutical innovations.

Conclusion

Chen Pan's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in vaccine development, are vital for addressing global health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…